

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

**Kiora Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

1371 East 2100 South  
Suite 200  
Salt Lake City, UT  
(Address of Principal Executive Offices)

98-0443284  
(IRS Employer  
Identification No.)

84105  
(Zip Code)

**Kiora Pharmaceuticals, Inc. 2014 Equity Incentive Plan**

(Full title of the plan)

Brian M. Strem, Ph.D.  
President and Chief Executive Officer  
Kiora Pharmaceuticals, Inc.  
1371 East 2100 South  
Suite 200  
Salt Lake City, UT 84105  
(Name and address of agent for service)

(781) 788-9043  
(Telephone number, including area code, of agent for service)

*Copies to:*

Robert A. Pettitt  
Burns & Levinson LLP  
125 High Street  
Boston, MA 02110  
Telephone: (617) 345-3000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**INCORPORATION BY REFERENCE OF PRIOR REGISTRATION STATEMENT**

This Registration Statement on Form S-8 is filed by Kiora Pharmaceuticals, Inc., a Delaware corporation (the "**Registrant**"), relates to 246,666 shares of its common stock, par value \$0.01 per share (the "**Common Stock**"), issuable under the Registrant's 2014 Equity Incentive Plan (as amended, the "**2014 Plan**") that have become reserved for issuance as a result of (i) the operation of the "evergreen" provision of the 2014 Plan, which provides that the total number of shares subject to such plan will be increased on January 1 of each of the ten (10) calendar years during the term of the 2014 Plan pursuant to a specified formula, and (ii) an increase of 200,000 shares of Common Stock to the number of shares of Common Stock available for issuance under the 2014 Plan pursuant to stockholder approval obtained on June 24, 2021.

The shares of Common Stock included on this Registration Statement are in addition to the shares of Common Stock relating to the 2014 Plan that were registered on the Registrant's Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "**Commission**") on [February 20, 2015](#) (SEC File No. 333-202207), on [February 9, 2016](#) (SEC File No. 333-209441), on [February 24, 2017](#) (SEC File No. 333-216227), on [March 2, 2018](#) (SEC File No. 333-223431), on [May 3, 2019](#) (SEC File No. 333-231207), and on [August 6, 2020](#) (SEC File No. 333-241657) (together, the "**Prior Registration Statements**").

This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate, and is submitted in accordance with General

**PART II**  
**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:

(a) The Registrant's Annual Report on [Form 10-K for the fiscal year ended December 31, 2021 filed with the Commission on April 15, 2022](#) pursuant to Section 13 of the Exchange Act;

(b) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the Registrant's Annual Report referred to in (a) above; and

(c) The description of the Registrant's Common Stock contained in the Registrant's Amendment No. 1 to Registration Statement on [Form 8-A \(File No. 001-36672\) filed with the Commission on July 30, 2015](#) under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Salt Lake City, State of Utah, on May 3, 2022.

KIORA PHARMACEUTICALS, INC.

By: /s/ Brian M. Strem, Ph.D.  
Brian M. Strem, Ph.D.  
President and Chief Executive Officer

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian M. Strem, Ph.D. and Susan L. Drexler, and each of them singly (with full power to each of them to act alone), as such person's true and lawful attorney in fact and agent with full power of substitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Brian M. Strem, Ph.D.</u> Brian M. Strem, Ph.D.	President, Chief Executive Officer and Director (principal executive officer)	May 3, 2022
<u>/s/ Susan L. Drexler</u> Susan L. Drexler	Interim Chief Financial Officer (principal financial and accounting officer)	May 3, 2022
<u>/s/ Paul Chaney</u> Paul Chaney	Chairman	May 3, 2022
<u>/s/ Kenneth Gayron</u> Kenneth Gayron	Director	May 3, 2022
<u>/s/ Praveen Tyle</u>	Director	May 3, 2022

---

Praveen Tyle

/s/ David Hollander  
David Hollander

Director

May 3, 2022

/s/ Aron Shapiro  
Aron Shapiro

Director

May 3, 2022

/s/ Erin Parsons  
Erin Parsons

Director

May 3, 2022

INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">4.1(1)</a>	<a href="#">Restated Certificate of Incorporation of Registrant</a>
<a href="#">4.2(2)</a>	<a href="#">Certificate of Amendment to the Restated Certificate of Incorporation of Registrant, filed July 10, 2018</a>
<a href="#">4.3(3)</a>	<a href="#">Certificate of Amendment to the Restated Certificate of Incorporation of Registrant, filed August 28, 2019</a>
<a href="#">4.4(4)</a>	<a href="#">Certificate of Amendment to the Restated Certificate of Incorporation of Registrant, filed June 25, 2020</a>
<a href="#">4.3(5)</a>	<a href="#">Second Amended and Restated Bylaws of Registrant</a>
<a href="#">4.4(6)</a>	<a href="#">Specimen common stock certificate of Registrant</a>
<a href="#">4.5(7)</a>	<a href="#">2014 Equity Incentive Plan, as amended</a>
<a href="#">5.1</a>	<a href="#">Opinion of Burns &amp; Levinson LLP</a>
<a href="#">23.1</a>	<a href="#">Consent of EisnerAmper LLP</a>
<a href="#">23.2</a>	<a href="#">Consent of Burns &amp; Levinson LLP (contained in Exhibit 5.1 hereto)</a>
<a href="#">24.1</a>	<a href="#">Power of Attorney (contained on signature page hereto)</a>
<a href="#">107</a>	<a href="#">Calculation of Filing Fee Table</a>

- (1) Incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed with the SEC on February 20, 2015.
  - (2) Incorporated by reference to Exhibit 3.2 filed with the Registrant's Current Report on Form 8-K filed with the SEC on July 11, 2018.
  - (3) Incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed with the SEC on August 29, 2019.
  - (4) Incorporated by reference to Exhibit 3.1 filed with the Registrant's Current Report on Form 8-K filed with the SEC on June 26, 2020.
  - (5) Incorporated by reference to Exhibit 3.2 filed with the Registrant's Current Report on Form 8-K filed with the SEC on November 8, 2021.
  - (6) Incorporated by reference to Exhibit 4.1 filed with the Registrant's Amendment No. 2 to Form S-1 Registration Statement (Registration No. 333-197725) filed with the SEC on August 29, 2014.
  - (7) Incorporated by reference to Exhibit 10.1 filed with the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021.
-

[Letterhead of Burns & Levinson LLP]

May 3, 2022

Kiora Pharmaceuticals, Inc.  
1371 East 2100 South  
Suite 200  
Salt Lake City, Utah 84105

**Re: Registration Statement on Form S-8**

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by Kiora Pharmaceuticals, Inc., a Delaware corporation (the **Company**), of a Registration Statement on Form S-8 (the **Registration Statement**) with the Securities and Exchange Commission covering the offering of up to an aggregate of 246,666 shares (the **Shares**) of the Company's Common Stock, par value \$0.01 per share (**Common Stock**), pursuant to the Company's 2014 Equity Incentive Plan (as amended, the **Plan**).

In connection with this opinion, we have examined and relied upon our review of (a) the Registration Statement and related prospectuses, (b) the Plan, (c) the Company's Restated Certificate of Incorporation and Second Amended and Restated Bylaws, each as currently in effect, and (d) such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware.

For purposes of the opinion expressed below, we have assumed that a sufficient number of authorized but unissued shares of Common Stock will be available for issuance when the Shares are issued.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, and the Registration Statement and related prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement.

Very truly yours,

/s/ Burns & Levinson LLP

Burns & Levinson LLP

---

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of Kiora Pharmaceuticals, Inc. on Form S-8 to be filed on or about May 3, 2022 of our report dated April 15, 2022, on our audit of the financial statements as of December 31, 2021 and 2020 and for each of the years then ended, which report was included in the Annual Report on Form 10-K. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

/s/ EisnerAmper LLP

EISNERAMPER LLP  
Iselin, New Jersey  
May 3, 2022

---

## Calculation of Filing Fee Tables

## FORM S-8

.....  
(Form Type)

## KIORA PHARMACEUTICALS, INC.

.....  
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered (1)	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
<b>Newly Registered Securities</b>								
Fees to Be Paid	Equity	Common Stock, par value \$0.01 per share <sup>(2)(3)(4)</sup>	Other	246,666 <sup>(2)</sup>	\$0.50 <sup>(3)</sup>	\$123,333	\$92.70 per \$1,000,000	\$11.43
		<b>Total Offering Amounts</b>				\$123,333		\$11.43
		<b>Total Fee Offsets</b>						\$0.00
		<b>Net Fee Due</b>						\$11.43

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 (the "Registration Statement") shall also cover any additional shares of the common stock, \$0.01 par value per share (the "Common Stock"), of Kiora Pharmaceuticals, Inc. (the "Registrant") that become issuable with respect to the securities identified in the above table, by reason of any stock dividend, stock splits, reverse stock splits, recapitalizations, reclassifications, mergers, split-ups, reorganizations, consolidations and other capital adjustments effected without receipt of consideration that increases the number of outstanding shares of Common Stock.
- (2) Represents (i) an automatic increase of 46,666 shares of Common Stock to the number of shares of Common Stock available for issuance on January 1, 2021 and January 1, 2022 pursuant to an "evergreen" provision under the Registrant's 2014 Equity Incentive Plan (the "2014 Plan"); and (ii) an increase of 200,000 shares of Common Stock to the number of shares of Common Stock available for issuance under the 2014 Plan pursuant to stockholder approval obtained on June 24, 2021.
- (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act on the basis of \$0.50, the average of the high and low prices of a share of Common Stock as reported on The Nasdaq Stock Market LLC on May 2, 2022.